Early Asset Evaluation

While it is common for opportunity assessments to be undertaken during late-stage clinical development, it has increasingly become a prerequisite for early-stage product development as well as portfolio decisions. Early horizon scanning and market landscape assessment allow companies to make prudent decisions and avoid foreseeable clinical and commercial pitfalls. It provides critical insights on program progress, product line extensions, and partnering decisions, allowing better decision-making for early commercial and Business Development & Licensing (BD&L) teams. When exploring new disease areas, Course5’s market attractiveness analysis provides an in-depth view of the target market in terms of new opportunities and threats.

Use Cases

Early Asset Prioritization in Oncology

Provide end-to-end conference coverage including primary and secondary intelligence gathering based on KITs and KIQs…

Next Steps

Get Started